British National Formulary January 2022 Update
This update contains 9 significant changes, 2 dose changes, 5 new monographs and 1 deleted preparation.
• Adrenaline/epinephrine auto-injectors: reminder for prescribers to support safe and effective use [MHRA/CHM advice].
• Arrhythmias: updated guidance for the management of atrial fibrillation.
• COVID-19: updated guidance.
• COVID-19 vaccines: updated guidance in-line with Public Health England/UK Health Security Agency recommendations.
• Dapagliflozin (Forxiga®) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus [MHRA/CHM advice].
• Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
• Mexiletine: update to include new indication for life-threatening ventricular arrhythmias.
• Phenobarbital: oral doses for children have been removed from the BNF; these can still be accessed in BNF for Children, where additional information on the available oral solutions and advice from the RCPCH/NPPG can be found in the prescribing and dispensing section of the Phenobarbital monograph.
• Yellow fever vaccine, live (Stamaril®): new pre-vaccination checklist [MHRA/CHM advice].
• Adrenaline/epinephrine [update to dosing for acute anaphylaxis].
• Calcium gluconate [update to dosing for acute severe hyperkalaemia].
• Lagevrio® [molnupiravir].
• Lumykras® [sotorasib].
• Ponvory® [ponesimod].
• Tepmetko® [tepotinib].
• Tukysa® [tucatinib].
Deleted Preparations: Tacni® [tacrolimus].
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699